How to evidence clinical development and operations experience

Separate development from operations

Clinical development commonly shapes questions about population, endpoints, benefit-risk and interpretation. Clinical operations commonly turns the protocol into a deliverable study through countries, sites, vendors, enrolment, quality and timelines. Structures vary, so describe what the team actually owned rather than relying on the department name.

For hybrid work, split the example into decisions. State who approved the protocol position, who selected the operational response and what you personally recommended or executed. This is more credible than claiming end-to-end ownership because you attended both workstreams.

Build a study evidence inventory

For each relevant study, record phase or design, indication, population, geography, status and your period of involvement. Add the decisions you influenced: feasibility, protocol design, endpoint implementation, country strategy, vendor oversight, recruitment recovery, data review, inspection readiness or close-out.

Protect confidential information. Public or permitted descriptors can demonstrate complexity without disclosing blinded results, participant information or commercially sensitive strategy. If a number cannot be supported or shared, describe the verified directional outcome precisely.

Show ownership and challenge

A useful example explains what was at risk, the evidence available, alternatives considered and why a course was chosen. Mention the governance forum and collaborators where relevant. Replace vague phrases such as drove strategy with the recommendation or decision you actually made.

Include challenge. Studies rarely progress without disagreement or constraint. Explain how you handled a recruitment assumption, endpoint issue, protocol deviation pattern, vendor problem or emerging safety concern while staying within authority and escalation requirements.

Use outcomes appropriate to the work

Operational outcomes can include milestone recovery, improved data quality, reduced query burden, resolved inspection findings or controlled vendor performance when the evidence supports them. Development outcomes can include a protocol decision, interpretable endpoint strategy, governance recommendation or evidence package milestone.

Do not imply that faster is always better. A justified pause, escalation or protocol change may be a stronger regulated outcome than a timeline gain. Connect the result to participant protection, evidence reliability or a documented programme decision.

Tailor to the target accountability

For a study-manager role, prioritise execution, vendors, sites, risk and delivery governance. For a clinical-scientist role, prioritise protocol rationale, data review, endpoint interpretation and scientific contribution. For leadership, show portfolio trade-offs, team decisions and cross-functional accountability.

End with the limits of the evidence. If you supported rather than approved a decision, say so. Accurate boundaries make strong experience easier to trust and reveal which interview questions must establish readiness for the next level.

A study-evidence template

Record study design and stage, population, countries, operational status, your dates, accountable function, personal decision, evidence considered, governance route, controlled output and verified result. Add a confidentiality check before using any detail externally.

Use separate rows when one project demonstrates different capabilities. Protocol contribution, vendor recovery and data-review support may belong to the same study but should not be combined into a claim of complete study ownership.

Sources and further reading

Authoritative sources support the regulated or employment context. The practical framework and interpretation are original PTTF editorial work.

1. Human medicines in the product lifecycle — European Medicines Agency
2. Compliance in the product lifecycle — European Medicines Agency